Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ketamine plus midazolam versus midazolam alone for initial control of generalized convulsive seizures
PACTR202511562566881Phase 2Not yet recruiting
- Sponsor
- Sohag for Pharmaceutical Industries
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of ketamine and midazolam in tonic-clonic seizure (GTCS), sponsored by Sohag for Pharmaceutical Industries. Primary endpoint: Cessation of clinical seizures at 5 minutes. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
ketaminemidazolam
03
Conditions
tonic-clonic seizure (GTCS)
Beyond the preview
Go deeper on PACTR202511562566881.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202511562566881.